GT201300252A - Alfa glucosidasa ácida modificada con procesamiento acelerado - Google Patents

Alfa glucosidasa ácida modificada con procesamiento acelerado

Info

Publication number
GT201300252A
GT201300252A GT201300252A GT201300252A GT201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A
Authority
GT
Guatemala
Prior art keywords
accelerated processing
modified acid
alfa
glucosidase modified
glucosidase
Prior art date
Application number
GT201300252A
Other languages
English (en)
Inventor
William M Canfield
Rodney J Moreland
Mariko Kudo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300252A publication Critical patent/GT201300252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONA UN POLIPÉPTIDO DE ALFA-GLUCOSIDASA ÁCIDA HUMANA MODIFICADA, QUE TIENE HIDROFOBICIDAD INCREMENTADA DE 70 KDA CERCA DEL EXTREMO N-TERMINAL, ASÍ COMO MÉTODOS PARA PRODUCIR Y USAR LA ALFA-GLUCOSIDASA ÁCIDA HUMANA MODIFICADA PARA TRATAR UNA GLUCOGENOSIS.
GT201300252A 2011-04-22 2013-10-18 Alfa glucosidasa ácida modificada con procesamiento acelerado GT201300252A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
GT201300252A true GT201300252A (es) 2015-02-09

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300252A GT201300252A (es) 2011-04-22 2013-10-18 Alfa glucosidasa ácida modificada con procesamiento acelerado

Country Status (23)

Country Link
US (1) US20140186326A1 (es)
EP (1) EP2699676A1 (es)
JP (2) JP2014513952A (es)
KR (1) KR20140037082A (es)
CN (1) CN103797115A (es)
AU (1) AU2012245280A1 (es)
BR (1) BR112013026976A2 (es)
CA (1) CA2833371A1 (es)
CL (1) CL2013003010A1 (es)
CO (1) CO6811810A2 (es)
CR (1) CR20130555A (es)
EC (1) ECSP13013036A (es)
GT (1) GT201300252A (es)
IL (1) IL228871A0 (es)
MA (1) MA35125B1 (es)
MX (1) MX2013012345A (es)
NI (1) NI201300110A (es)
PE (1) PE20140617A1 (es)
RU (1) RU2013151875A (es)
SG (2) SG194486A1 (es)
TN (1) TN2013000427A1 (es)
WO (1) WO2012145644A1 (es)
ZA (1) ZA201307696B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
BR112017005810A2 (pt) 2014-09-30 2018-02-27 Amicus Therapeutics Inc alfa-glucosidase ácida altamente potente com carboidratos melhorados
CA3003750A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
BR112018070189A2 (pt) 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3510149A1 (en) 2016-09-12 2019-07-17 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
JP2022540632A (ja) 2019-07-09 2022-09-16 ジェネトン 糖原病（ｇｓｄ）の処置
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
CA2530020A1 (en) 2003-06-24 2005-01-06 Genzyme Corporation Novel .beta.-actin and rps21 promoters and uses thereof
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2889043B1 (en) 2008-12-16 2019-04-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
SG10201605874TA (en) 2016-09-29
TN2013000427A1 (en) 2015-03-30
US20140186326A1 (en) 2014-07-03
CA2833371A1 (en) 2012-10-26
EP2699676A1 (en) 2014-02-26
MA35125B1 (fr) 2014-05-02
WO2012145644A1 (en) 2012-10-26
CL2013003010A1 (es) 2014-03-07
SG194486A1 (en) 2013-12-30
RU2013151875A (ru) 2015-05-27
CN103797115A (zh) 2014-05-14
AU2012245280A1 (en) 2013-11-07
KR20140037082A (ko) 2014-03-26
ZA201307696B (en) 2014-07-30
NI201300110A (es) 2014-02-28
CR20130555A (es) 2013-12-09
JP2014513952A (ja) 2014-06-19
PE20140617A1 (es) 2014-05-28
IL228871A0 (en) 2013-12-31
BR112013026976A2 (pt) 2019-09-24
MX2013012345A (es) 2015-05-07
CO6811810A2 (es) 2013-12-16
JP2017035091A (ja) 2017-02-16
ECSP13013036A (es) 2015-04-30

Similar Documents

Publication Publication Date Title
GT201300252A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
PH12020550529A1 (en) Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
CL2018000671A1 (es) Expresión de proteínas recombinantes en pupas de trichoplusia ni
BR112017025322A2 (pt) métodos integrados para tratamento de material lignocelulósico
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
UY33956A (es) Anticuerpo del factor antitisular humano y sus usos para tratar cáncer
BR112013020652A2 (pt) processo para produção de uma fibra de lignina
DOP2015000187A (es) Proceso de fabricación de vortioxetina
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
BR112015030655A2 (pt) Variantes de xilanase e polinucleótidos que codificam as mesmas
CL2015002634A1 (es) Composiciones de fascia fibrosa y métodos para su uso y manufactura
BR112018015926A2 (pt) processos para preparação de uma solução aquosa e para mineralização e/ou estabilização de água, e, uso de uma solução aquosa.
BR112018010631A2 (pt) uso de oxigênio dissolvido para inibir a produção de ácido láctico durante a propagação de levedura e/ou hidrólise de biomassa de lignocelulose
BR112015022266A2 (pt) processo e sistema eletroquímicos para a produção de glicose
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MY182182A (en) Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
BR112016029572A2 (pt) variantes de exoglucanases que possuem atividade melhorada e utilizações das mesmas
UY34408A (es) Nuevos moduladores de trpv3
BR102012023867A2 (pt) Método de pré-tratamento para produzir açúcares solúveis em água a partir de material lignocelulósico
BR112016021284A2 (pt) Processos para produção de glicoproteínas recombinantes com glicosilação modificada